Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Conditions
Insulin-like Growth Factor-1 Deficiency
Interventions
NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Drug
Lead sponsor
Ipsen
Industry
Eligibility
5 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Brisbane, California
Completed Phase 2 Interventional Accepts healthy volunteers

Calcium and Bone Mass in Young Females

NCT00000402
Conditions
Osteoporosis
Interventions
Calcium
Drug
Lead sponsor
Ohio State University
Other
Eligibility
8 Years to 13 Years · Female only
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2001
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
PCOS (Polycystic Ovary Syndrome), Puberty, Insulin Resistance, Physical Activity
Interventions
ActiveGirls Physical Activity Program (Full), ActiveGirls Physical Activity Program (Delayed Lower Intensity)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Somerville, Massachusetts
Conditions
Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Central Precocious Puberty
Interventions
Debio 4326
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
5 Years to 8 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Columbia, South Carolina
Conditions
Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Adolescent Obesity, Pre Diabetes, Kidney Hypoxia, Puberty
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40
Drug
Lead sponsor
Petter Bjornstad
Other
Eligibility
8 Years to 14 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism, Normal Puberty
Interventions
Progesterone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Central Precocious Puberty (CPP)
Interventions
Leuprolide Acetate (LA)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Long Beach, California • San Diego, California • Aurora, Colorado + 14 more
Suspended No phase listed Observational Accepts healthy volunteers

Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia

NCT02611128
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism, Puberty
Interventions
Phenotype/genotype assessment
Other
Lead sponsor
University of Virginia
Other
Eligibility
8 Years to 17 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Hypogonadism, Hypergonadism, Precocious Puberty, Late Puberty, Amenorrhea
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
8 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Conditions
Puberty, Precocious
Interventions
Bicalutamide, Anastrozole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 13 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • Jacksonville, Florida • Indianapolis, Indiana + 6 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Follicle-Stimulating Hormone (FSH) and the Onset of Puberty

NCT00734279
Conditions
Delayed Puberty, Precocious Puberty
Interventions
Leuprolide Acetate - Early Puberty Leuprolide Visit, Ganirelix - Early Puberty Ganirelix Visit, Ganirelix - Delayed Puberty Ganirelix Visit, Leuprolide Acetate- Delayed Puberty Leuprolide Visit
Drug
Lead sponsor
University of Utah
Other
Eligibility
6 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Endocrine Disease, Infertility, Hypogonadism, Amenorrhea, Adolescents
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
14 Years to 100 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
2
States / cities
Bethesda, Maryland • Research Triangle Park, North Carolina
Conditions
Hypogonadotropic Hypogonadism, Kallmann Syndrome, Puberty, Delayed, Puberty, Precocious, GnRH Deficiency
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
4,042 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

STAGES Trial: Study of Adiposity, Growth and Endocrine Stages

NCT01460784
Conditions
Obesity
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 30 Years
Enrollment
575 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Puberty, Hyperandrogenism
Interventions
Micronized progesterone suspension, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Overweight/Obesity, Puberty, Health Behavior, Cardiometabolic Health
Interventions
Family-Based Treatment (FBT)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
6 Years to 8 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Polyostotic Fibrous Dysplasia, Precocious Puberty
Interventions
Testolactone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1982 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Recruiting No phase listed Observational Accepts healthy volunteers

Functional Ovarian Reserve in Sickle Cell Disease

NCT07392216
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
10 Years to 18 Years · Female only
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2034
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Puberty; Precocious, Central
Interventions
Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide
Drug
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Industry
Eligibility
2 Years to 9 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • San Diego, California • Jacksonville, Florida + 7 more
Conditions
Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa), Tanner Staging, Depot Formulation, Suppression of LH, Central Precocious Puberty (CPP), Gonadotrophin-releasing Hormone (GnRH), Lupron, GnRH Analog, Pediatrics Central Precocious Puberty
Interventions
Leuprolide Acetate 3 Month Depot
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 13 more
Conditions
Klinefelter Syndrome
Interventions
Counseling
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 25 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Obesity
Interventions
Weight loss intervention, No Weight loss intervention
Behavioral
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
5 Years to 12 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Recruiting No phase listed Observational Accepts healthy volunteers

Data Collection Study of Pediatric and Adolescent Gynecology Conditions

NCT04717349
Conditions
Disorders of Sex Development (DSD), Pediatric and Adolescent Cancers of the Genital Tract, Reproductive Endocrine Conditions in Puberty, Structural Gynecologic Conditions Including Vulvar and Vaginal Conditions
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Day to 100 Years
Enrollment
11,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2039
U.S. locations
1
States / cities
Bethesda, Maryland